Crossmark Global Holdings Inc. Decreases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Crossmark Global Holdings Inc. lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 24.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 27,323 shares of the company’s stock after selling 8,787 shares during the period. Crossmark Global Holdings Inc.’s holdings in Eli Lilly and Company were worth $21,093,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Beck Bode LLC bought a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $15,036,000. Sfmg LLC raised its holdings in Eli Lilly and Company by 5.8% in the 2nd quarter. Sfmg LLC now owns 3,219 shares of the company’s stock worth $2,915,000 after purchasing an additional 177 shares in the last quarter. Royal Capital Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 5.2% in the 2nd quarter. Royal Capital Wealth Management LLC now owns 3,869 shares of the company’s stock worth $3,502,000 after purchasing an additional 191 shares during the period. Insigneo Advisory Services LLC boosted its stake in shares of Eli Lilly and Company by 14.9% during the 2nd quarter. Insigneo Advisory Services LLC now owns 7,000 shares of the company’s stock valued at $6,338,000 after purchasing an additional 908 shares in the last quarter. Finally, Wescott Financial Advisory Group LLC increased its position in shares of Eli Lilly and Company by 8.7% during the second quarter. Wescott Financial Advisory Group LLC now owns 9,274 shares of the company’s stock valued at $8,396,000 after buying an additional 744 shares during the period. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective on the stock. Barclays decreased their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. Truist Financial upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Finally, Citigroup upped their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $1,002.22.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $753.65 on Thursday. The business has a 50-day simple moving average of $777.46 and a two-hundred day simple moving average of $851.61. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The firm has a market cap of $715.46 billion, a price-to-earnings ratio of 81.48, a price-to-earnings-growth ratio of 1.52 and a beta of 0.41. Eli Lilly and Company has a fifty-two week low of $614.82 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter last year, the company earned $0.10 EPS. The firm’s revenue for the quarter was up 20.4% on a year-over-year basis. On average, analysts expect that Eli Lilly and Company will post 12.98 earnings per share for the current year.

Eli Lilly and Company announced that its Board of Directors has initiated a stock repurchase plan on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to purchase up to 2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.80%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s payout ratio is presently 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.